This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Top Analyst Reports for SAP, Goldman Sachs & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), The Goldman Sachs Group, Inc. (GS) and Lockheed Martin Corp. (LMT), as well as two micro-cap stocks AMREP Corp. (AXR) and Nova LifeStyle, Inc. (NVFY).
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside
by Nalak Das
Four S&P 500 laggards of this year have double-digit upside left for the rest of 2024. These are: CCL, PFE, ZTS, TDY.
If You Invested $1000 in Zoetis a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
by Zacks Equity Research
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.
Zoetis (ZTS) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the most recent trading session, Zoetis (ZTS) closed at $191.09, indicating a +0.2% shift from the previous trading day.
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for SAP, Cisco & Intuit
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Cisco Systems, Inc. (CSCO) and Intuit Inc. (INTU), as well as two micro-cap stocks Team, Inc. (TISI) and Miller Industries, Inc. (MLR)
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zoetis (ZTS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Zoetis (ZTS) Just Overtook the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Zoetis (ZTS) Just Reclaimed the 200-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
Zoetis (ZTS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.
Tech Giants Lead Market Selloff
by Zacks Equity Research
Tech Giants Lead Market Selloff
U.S. Stock Futures in Green After Three Days of Devastation
by Zacks Equity Research
U.S. Stock Futures in Green After Three Days of Devastation.
Zoetis (ZTS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 4.70% and 2.53%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
UTHR or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTHR vs. ZTS: Which Stock Is the Better Value Option?